Overview
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Status:
Terminated
Terminated
Trial end date:
2014-05-01
2014-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Kadmon Corporation, LLCTreatments:
Erlotinib Hydrochloride
Criteria
For Eligibility subjects must have:- failed one or two previous courses of therapy.
- have no active brain metastasis. Treated non-active brain metastasis are acceptable.
- cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva
[erlotinib] or Iressa [gefitinib]) in the past.
- has demonstrated progressive disease.